While Supernus Pharmaceuticals Inc has underperformed by -3.58%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SUPN rose by 52.56%, with highs and lows ranging from $39.37 to $23.05, whereas the simple moving average jumped by 18.65% in the last 200 days.
On September 11, 2024, Piper Sandler Downgraded Supernus Pharmaceuticals Inc (NASDAQ: SUPN) to Neutral. Jefferies also rated SUPN shares as ‘Buy’, setting a target price of $44 on the company’s shares in an initiating report dated December 01, 2021. Jefferies April 13, 2021d the rating to Buy on April 13, 2021, and set its price target from $25 to $40. Piper Sandler June 16, 2020d its ‘Neutral’ rating to ‘Overweight’ for SUPN, as published in its report on June 16, 2020. Jefferies’s report from June 15, 2020 suggests a price prediction of $24 for SUPN shares, giving the stock a ‘Hold’ rating. Berenberg also rated the stock as ‘Hold’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Supernus Pharmaceuticals Inc (SUPN)
Further, the quarter-over-quarter increase in sales is 14.17%, showing a positive trend in the upcoming months.
One of the most important indicators of Supernus Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 6.22% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.98, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and SUPN is recording 395.91K average volume. On a monthly basis, the volatility of the stock is set at 3.61%, whereas on a weekly basis, it is put at 7.21%, with a gain of 6.84% over the past seven days. Furthermore, long-term investors anticipate a median target price of $39.25, showing growth from the present price of $36.40, which can serve as yet another indication of whether SUPN is worth investing in or should be passed over.
How Do You Analyze Supernus Pharmaceuticals Inc Shares?
The Drug Manufacturers – Specialty & Generic market is dominated by Supernus Pharmaceuticals Inc (SUPN) based in the USA. When comparing Supernus Pharmaceuticals Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 34.08, there is a growth in quarterly earnings of 334.94%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.25%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 108.38% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SUPN shares are owned by institutional investors to the tune of 108.38% at present.
